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Certain peptides containing high percentage of cationic amino acids are known to efficiently translocate through the cell membrane. This
principle was previously exploited for delivery of variety proteins. We had observed that various basic peptides of earlier studies, though not
specifically use for gene delivery, contain DNA or RNA binding domains. In the present study, we reported on arginine peptides, which form
DNA complexes that efficiently transfect various cell lines. The transfection abilities of the peptides were observed by green fluorescent
protein (GFP) and h-galactosidase gene expression in 293T, HeLa, Jurkat, and COS-7 cells. We found superior transfection activity of
arginine peptides compared with commercially available efficient transfection agents. The expression of marker genes induced by arginine
peptides was partially inhibited in the presence of heparan sulfate, chondroitin sulfate B and C, or both heparinase III and chondroitinase
ABC. The transfection proficiency of these peptides was affected by endosomotropic reagent as well as low temperature (4 jC). Finally, we
have investigated the potential of arginine peptides as a delivery agent for gene therapy, by attempting to deliver herpes simplex virus
thymidine kinase (HSV-TK) gene into tumor cells. HSV-TK transfected tumor cells exhibited sensitivity to the antiviral drug ganciclovir
(GCV), leading to cell death. Taken together, these data demonstrate that arginine peptide is proficient for transfection, indicating its
potentially benefit to studies in gene therapy and gene delivery in a range of model organisms.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Arginine peptide; Gene delivery; Gene therapy; Proteoglycan1. Introduction
Systems for delivery of exogenous proteins into living
cells were previously developed by fusion of the target
protein with membrane-permeable carrier peptides such as
HIV-1 Tat-(48–60) [1–5]. By genetically or chemically
hybridizing these carrier peptides, efficient intracellular
delivery of various proteins larger than 100 kDa was
achieved [6]. Intraperitoneal injection of the peptide-h-
galactosidase fusion (120 kDa) resulted in delivery of the
protein to various tissues in mice including the brain [6],
opening new possibilities for therapeutic delivery of pro-
teins into patients.
Besides Tat protein, other transduction domains have
been identified from the Antennapedia (Antp) protein of
Drosophila [7] and from the HSV VP22 protein in herpes0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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mechanisms of protein transduction across cellular mem-
branes remain unclear. However, the shared feature of these
carrier proteins is that these proteins consist of highly basic
and hydrophilic peptides. In the case of Tat-(48–60), the
carrier proteins contain six arginine and two lysine residues
among its 13 amino acids, suggesting that the arginine
sequence is itself a critical motif for the efficient delivery
of exogenous proteins into cells. Subsequent investigation
demonstrated that peptides composed only arginine residues
were able to translocate cell membranes efficiently and
accumulate in nucleus [9,10].
Despite the high proficiency displayed by these arginine-
rich peptide carriers, little is known about gene transfer
mediated by arginine peptide. Recent reports showed that
basic peptides containing DNA or RNA binding motifs
could translocate into the target cells [9,11]. These peptides
include numerous viral proteins, such as HIV-1 Rev and
flock house virus coat protein, the DNA binding segments
of leucine zipper proteins, such as cancer-related proteins c-
Fos and c-Jun, and the yeast transcription factor GCN4ed.
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peptides could deliver not only proteins but also nucleotides
into the target cells.
At present, the most prevalent gene delivery technique
employs viral vectors, which provide efficient transduc-
tion and high level of gene expression, but also have
drawbacks such as immunogenic and transgene activity
[13,14]. As an alternative to viral vectors, recent peptide-
based vectors have been widely investigated due to the
advantage of safety and low cost of manufacture [13,15].
In addition, peptide-based vectors provide the flexibility
of DNA carrying capacity and simplicity of use. How-
ever, maximal transfection efficiencies with these vectors
require peptide modification that increases the molecular
weight of vectors [16,17]. These modifications, using a
range of moieties, entail cumbersome polymerization and
result time-consuming transfection schemes such as prep-
aration of vector. Consequently, the present study inves-
tigates the possibility of avoiding these modifications by
utilizing short arginine-rich peptides as efficient peptide
vectors.
Here, we demonstrate that arginine-rich peptides, which
form complex with DNA, promote the efficient transfection
of mammalian cells. We also examined mechanism of the
internalization of arginine peptide/DNA complex by chal-
lenge with glycosaminoglycans and glycosaminoglycan
lyases as well as endosomotropic reagent. In addition,
arginine-rich peptide was successfully used to deliver a
full-length herpes simplex virus thymidine kinase (HSV-
TK) gene, suicide gene, into tumor cells, generating ganci-
clovir (GCV)-enhanced cytotoxicity in these cells, findings
that underscore the potential of this peptide for efficient
gene therapy.
Basic peptides also enable protein to cross the blood–
brain barrier, and thus complexes formed between basic
peptides and genes might be an ideal means to deliver
therapeutic compounds to the organism, providing advan-
tages of both protein transduction and gene therapy.2. Materials and methods
2.1. Chemicals and reagents
GenePORTER2 was obtained from Gene Therapy
System (San Diego, USA). Lipofectin, h-gal assay kit,
and pcDNA3.1/His/LacZ plasmids encoding h-galactosi-
dase were from Invitrogen (Carlsbad, USA). MTT assay
kit was from Boehringer Mannheim (Indianapolis, USA).
Heparan sulfate, chondroitinase ABC, heparinase III, and
chondroitin sulfate A, B, C were furnished by Sigma-
Aldrich (Saint Louis, USA). Plasmid encoding the
enhanced green fluorescent protein (pEGFP-N3) was
purchased from Clonetech (Palo Alto, USA). All chem-
icals were provided by Sigma-Aldrich unless otherwise
stated.2.2. Peptide synthesis
Peptides employed in the experiments were arginine
peptides (R9-R15). These peptides were prepared by
solid-phase peptide synthesis using standard Fmoc (9-fluo-
renylmethyloxycarbonyl) chemistry. HPLC analysis indi-
cated all were at least 95% purity. The peptides were
dissolved in phosphate-buffered saline (PBS) to appropriate
concentrations.
2.3. Cell culture
The cell lines 293T, COS-7, HeLa, and Jurkat were
cultured in DMEM medium with 10% heat-inactivated fetal
bovine serum and 1% antibiotics (streptomycin + penicillin).
Cells were grown in 24-well plates and incubated at 37 jC
incubator containing 5% CO2 atmosphere.
2.4. Gel retardation and DNase I protection assays
To determine the optimal relative concentrations to
form peptide/DNA complexes, 0.5 Ag of plasmid DNA
was incubated with the indicated amount of arginine
peptide for 1 h at room temperature (25 jC) in serum-
free media, with a peptide/DNA charge ratio ranging
from 0:1 to 16:1. The peptide/DNA complexes were then
analyzed by 1% agarose gel electrophoresis. For the
nuclease protection assay, peptide/DNA complexes were
incubated at 37 jC in the presence or absence of DNase
I (0.5 Ag/ml).
2.5. Peptide-mediated plasmid transfection
To evaluate peptide-mediated gene transfection, the indi-
cated amounts or concentrations of peptides (up to 5 AM)
and plasmid DNA (0.5 Ag) were mixed into 300 Al serum-
free media, and complexes were formed for 1 h at room
temperature, after which 10% serum was added. The com-
plex was gently added to the cells, followed by incubation
for 2 h at 37 jC in 5% CO2 atmosphere. The cultures were
then washed once with serum-free media and transferred to
complete media for growth. After 48 h, GFP and h-gal gene
expressions were monitored. To evaluate the serum effect,
cells were incubated with peptide/DNA complexes for 2 h in
the presence or absence of serum prior to adding complete
media. GenePORTER2- and Lipofectin-mediated transfec-
tions were performed as described by the manufacturer’s
protocol.
2.6. GFP detection
The specified amount of each peptide/pEGFP-N3 plas-
mid complex was incubated with different cell types in
24-well plates, and expression of GFP protein was
detected by fluorescence microscopic analysis (Nikon,
Diaphot 300).
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Expression of h-galactosidase genes was measured after
48-h incubation at 37 jC in 5% CO2 with h-gal assay kit
according to the manufacturer’s instruction. The transfected
293T cells were washed once with PBS and lysed with lysis
buffer (20 Al/well). Cell debris was removed by centrifuga-
tion at 12,000 g and 1 Al of the supernatant added to 50 Al
of cleavage buffer containing h-mercaptoethanol and o-
nitrophenyl h-D-galactopyranoside (ONPG) solution. After
incubation for 30 min at 37 jC, the absorbance at 420 nm
was measured. The total protein concentrations in cell
lysates were determined using BCA assay (Pierce Chem-
ical).
2.8. MTT assay
The MTT assay was conducted essentially according to
the manufacturer’s protocol. Briefly, cells (1104/well)
were plated on 96-well microtiter plates in DMEM medium
with 10% heat-inactivated fetal bovine serum in the pres-
ence of serially diluted concentrations of the indicated
peptides ranging up to 100 AM. After 48-h incubation with
peptides, MTT (0.5 mg/ml) was added to each well. Cells
were incubated with MTT for 4 h. The insoluble formazan
was dissolved overnight in solubilization solution. Cell
viability was assessed by measuring the absorbance at 570
nm and expressed as the ratio of the A570 of cells treated
with peptide over the control samples.
2.9. Effects of glycosaminoglycans, glycosaminoglycan
lyases, and chloroquine on transfection efficiency of
peptides
293T cells were treated with glycosaminoglycans and
glycosaminoglycan lyases essentially as described as before
[18]. To evaluate the effect of glycosaminoglycans on
transfection, peptide/DNA complex and soluble chondroitin
A, B, C (40 Ag/ml each) and heparan sulfate (40 Ag/ml)
were added together at the time of transfection. Transfected
cells were treated according to the usual protocol. To test
glycosaminoglycan lyases effect, cells were incubated with
heparinase III (0.5 U/ml) and chondroitinase ABC (0.5 U/
ml) for 30 min. Cells were then washed gently with serum-
free medium and transfected according to the usual proto-
col. For endosomotropic reagent experiment, with chloro-
quine (50 AM), cells were preincubated for 30 min at 37 jC.
Then cells were rinsed extensively with serum-free medium
and peptide/DNA complexes were added. After 48-h incu-
bation, transfection efficiency was determined by h-gal
assay.
2.10. HSV-TK transfection
To generate HSV-TK expressing cells, the HSV-TK gene
was inserted into corresponding sites of pcDNA3.1 plas-
H.H. Kim et al. / Biochimica et Bmids, to create HSV-thymidine kinase-encoding constructs.
For gene transfections, the cervical cancer cell line HeLa
was cultured at 3 104 cells per well in 24-well plates.
DNA (0.5 Ag) in serum-free DMEM (50 Al) was added to
the solution of peptide in serum-free DMEM (250 Al),
allowed to stand for 1 h at room temperature, and the
peptide/DNA complex, in 10% FBS, was gently added to
the cells. After incubation for 2 h at 37 jC, the media was
replaced with fresh DMEM containing 10% FBS. Following
a further incubation for 48 h, the control cells and peptide-
mediated transfected cells were split, and then cultured in
the absence or presence of 10 AM GCV for 4 days. Cell
viability was determined using MTT assay. Percent viability
in transfected cell was expressed by the ratio of OD
absorption in the following equation.
Cell viability ð%Þ ¼ A570ðGCV  added cellsÞ
A570ðGCV  non added cellsÞ3. Results
3.1. Formation of peptide/DNA complexes
To assess formation of peptide/DNA complexes, gel
electrophoretic retardation was employed to measure the
electrostatic interaction in the complexes as a function of
the positive peptide/negative DNA charge ratios. The
results showed that the electrophoretic migration of
DNA was retarded with increasing ratio of peptides
(positive)/DNA (negative) (Fig. 1A). No migration of
plasmid DNA band was observed at charge ratio 3.0 or
higher. This absence of migration was probably due to the
neutralization of nucleic acid by cationic peptide and/or
formation of a large complex between the peptide and the
DNA [19].
Since the sensitivity of DNA to nucleases is a major
concern in efficient delivery, we investigated the suscepti-
bility of the complex DNA to DNase I. The peptide/DNA
complexes were therefore exposed to DNase I, and the
integrity of the plasmid DNA was analyzed. The data
showed that in the peptide/DNA complex of charge ratio
3:1, DNAwas fully protected against DNase I (Fig. 1B, lane
12) while the plasmids with lower concentration of arginine
peptide were either partially (Fig. 1B, lanes 8 and 10) or
completely degraded by the nuclease (lanes 4 and 6). These
results suggest that arginine peptide is sufficient to fully
protect DNA from DNase I and thus for protection from
similar intracellular nuclease.
In order to the use of arginine peptide as a DNA
delivery agent, the degree of cytotoxicity of peptides was
evaluated. HIV-1 Tat-(48–60) was previously reported to
exhibit low toxicity to HeLa cells [5]. Similarly, MTT assay
showed that several basic peptides such as R9-Tat, HIV-1
Fig. 1. Formation of the peptide/DNA complex. (A) Agarose gel-shift
assay. The pcDNA3.1/His/LacZ plasmid encoding the reporter protein h-
galactosidase was incubated for 1 h at room temperature with different
concentrations of arginine peptides (R15), corresponding to peptide/DNA
charge ratios range between 0 and 16, as indicated above each lane. The
performed complexes were analyzed by electrophoresis on 1% agarose gel
stained with ethidium bromide. Lane 1, DNA only; lane 2–10, charge ratio
of 0.25, 0.5, 1, 2, 3, 4, 8, and 16, respectively. (B) DNase I protection assay.
The plasmid DNA was preincubated with the various peptide/DNA charge
ratios indicated above each lane and complexes were exposed to DNase I
followed by analysis with 1% agarose gel electrophoresis. Peptide/DNA
complexes were incubated without (lane 1, 3, 5, 7, 9, 11) or with (lane 2, 4,
6, 8, 10, 12) DNase I in the presence of increasing concentrations of
peptide: lane 1, 2 (DNA only); lane 3, 4 (charge ratio 0.25:1); lane 5, 6
(charge ratio 0.5:1); lane 7, 8 (charge ratio 1:1); lane 9, 10 (charge ratio
2:1); lane 11, 12 (charge ratio 3:1).
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showed little or no cytotoxicity in macrophage cells upon
the treatment with peptide (10 AM) for 24 h [9]. Consistent
with these data, we observed no significant impairment to
cell survival even at 100 AM of R15 for 48 h: both 293T
and HeLa cells displayed greater than 95% survival rate
(data not shown).
3.2. Transfection of DNA by peptides
Since basic peptides did not induce cytotoxicity and are
known to bind DNA, we tested the possibility of R-rich
basic peptide-mediated gene delivery. Accordingly, R15
was mixed with plasmid DNA encoding GFP and incu-
bated with 293T, HeLa, COS-7, and Jurkat cells. Unless
otherwise noted, transfection was performed with peptide/
DNA charge ratio 3.0 and transfection efficiencies were
evaluated using fluorescence microscopic analysis of GFP
expression. The results showed that arginine peptides wereable to mediate translocation of plasmids into cells (Fig.
2).
Basic peptide-specific gene delivery was further con-
firmed by examining the dose effects of arginine peptide on
transfection efficiency in 24-well plates, using the h-gal
expression plasmid pcDNA3.1/His/LacZ. Plasmid (0.5 Ag)
was incubated with different concentrations of peptide,
corresponding the peptide/DNA charge ratios from 0:1 to
16:1. Maximal transfection and expression of h-galactosi-
dase obtained for a peptide/DNA charge ratio 3:1 corre-
spond to 1 AM concentration of peptide in both 293T and
HeLa cell lines (Fig. 3).
To further optimize transfection condition, we then
tested the effects of serum on R15-mediated transfection
activity. To this end, R15 were simply mixed with 0.5 Ag
of plasmids and allowed to form peptide/DNA complexes
by incubating at room temperature for 1 h. Transfection
was then initiated by adding the complexes to the cultures
for 2 h in the presence or absence of serum (10% FBS)
and the cultures were washed once with serum-free media
and replaced with complete media. Transfection efficiency
was then evaluated by measuring the efficiency of expres-
sion of reporter gene h-galactosidase. The results in the
presence or absence of serum were very similar (data not
shown), suggesting that transfection efficiency was not
affected by serum.
3.3. Comparison of arginine peptide with commercially
available transfection agents
The transfection efficiency of peptides was compared to
that of commercially available nonviral transfection reagents,
Lipofectin and GenePORTER2, using a reporter gene encod-
ing h-galactosidase. The expression efficiencies of h-galac-
tosidase were determined at 48 h after transfection by
measurement of the total enzyme activity in the cell extracts
of the cultured cells. As shown in Fig. 4, arginine peptide
yielded significantly higher h-gal transfection than either of
the commercial transfection agents. A significant positive
dependence of transfection efficiency on the number of
arginine residues was also observed. The efficiency obtained
from R15 residues was almost sevenfold higher than the
efficiency from Lipofectin.
3.4. Translocation mechanism of peptide/DNA complexes
Recently it has been reported that HIV-Tat and its
protein transduction domain (PTD) bind cell surface
heparan sulfate proteoglycan through their positively
charged basic domain [18,20]. It also suggested a role
for proteoglycan in cationic lipid-mediated gene transfer
[21,22]. Proteoglycan is widely distributed on cell surface
and mainly involved in cell–matrix interaction [23]. To
determine whether proteoglycan is involved in peptide-
mediated gene expression, we tested the effect of soluble
glycosaminoglycans on gene transfer. Cells were incubated
Fig. 2. Peptide-mediated pEGFP-N3 plasmid delivery in various cell lines. Peptides (R15) were respectively mixed with plasmid pEGFP-N3 charge ratio of 3.0
and allowed to stand for 1 h at room temperature in serum-free media. Various cell lines were incubated with peptide/DNA complexes with 10% FBS for 2 h at
37 jC, and then medium was replaced by complete media. The fluorescence microscopic analysis was performed 48 h after transfection. (A) 293T, (B) COS-7,
(C) Jurkat, (D) HeLa, (E) corresponding phase contrast image of HeLa cells, (F) DNA only in HeLa.
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saminoglycans. As shown in Fig. 5, heparan sulfate,
chondroitin sulfate B and C caused an inhibition of
transfection activity. In addition, we also studied the effect
of glycosaminoglycan lyases, which degrade the heparanFig. 3. The effect of charge ratio on transfection of the peptide/DNA
complexes. Cells (293T or HeLa) were incubated in the presence of
preformed peptide/DNA complex (varying in the peptide/DNA charge ratio
up to 16:1) for 2 h, after which they were replaced in the complete medium.
Forty-eight hours later, cell extracts were prepared and their h-gal activities
were determined as described in Materials and methods. Experiments were
performed at least three times at each sample; data shown are mean value
and S.D. for each measurement.
Fig. 4. Comparison of transfection efficiency of arginine peptides having a
different number of arginine residues, Lipofectin, and GenePORTER2.
Peptides were respectively mixed with plasmid pcDNA3.1/His/LacZ at a
peptide/DNA charge ratio of 3.0 and allowed to stand for 1 h at room
temperature in serum-free media. 293T cells were incubated with peptide/
DNA complexes with 10% FBS for 2 h at 37 jC, and then medium was
replaced by complete media. The cells were harvested and h-gal assay was
performed 48 h after transfection. Transfection using GenePORTER2 and
Lipofectin was similarly conducted as mentioned above. Following the
manufacturer’s protocol, Lipofectin (5 Al) and GenePORTER2 (2.5 Al) were
employed for 0.5 Ag of plasmid. Experiments were performed at least three
times at each sample; data shown are mean value and S.D. for each
measurement.
Fig. 6. Effects of incubation temperature and time on peptide-mediated
transfection. For temperature experiment (A), the 293T cells were incubated
with peptide/DNA complexes for 2 h at 4 jC or at 37 jC. After incubation,
the cultures were then washed once with serum-free media and transferred
to complete media. After 48 h, cells were harvested and h-gal activity was
determined. For time-dependent experiment (B), the peptide/DNA com-
plexes were added to the culture medium of 293T cells. At the indicated
time points, transfection was finished. The cultures were then washed once
with serum-free media and transferred to complete media. After 48 h, cells
were harvested and h-gal activity was determined. Experiments were
performed at least three times at each sample; data shown are mean value
and S.D. for each measurement.
Fig. 5. Effects of glycosaminoglycans, glycosaminoglycan lyases, and
chloroquine on peptide-mediated transfection. 293T cells were treated with
chondroitin sulfate A, B, and C (40 Ag/ml), or heparan sulfate (40 Ag/ml) at
the time of transfection. To test effect of lyases on transfection, cells were
preincubated in the presence of either chondroitinase ABC (0.5 U/ml) or
heparinase III (0.5 U/ml) for 30 min and then transfected as described in
Materials and methods. Cells were treated with chloroquine (50 AM) 30 min
before addition of peptide/DNA complex. Then cells were rinsed
extensively with serum-free medium, and peptide/DNA complexes were
added. The cells were harvested and h-gal assay was performed 48 h after
transfection. Experiments were performed at least three times at each
sample; data shown are mean value and S.D. for each measurement.
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transfer. We found that heparinase III inhibits peptide-
mediated gene transfer to 60% of the control values.
Taken together, our results indicate that proteoglycan plays
an important role in the process of peptide-mediated gene
transfer.
It is not clear whether PTD-mediated macromolecule
transduction via temperature independently or dependently
[2,9,24]. Therefore, we characterized the rate of peptide-
mediated gene transfer at various temperatures. Incubation
of cells with peptide/DNA complex at 4 jC reduced
expression by approximately 70% compared with expres-
sion at 37 jC (Fig. 6A). To further characterize the
transport route of peptide/DNA complex, marker gene
expression was studied by varying the time of incubation
of the cells with peptide/DNA complex. The expression of
h-gal gene increased gradually with increased exposure of
cells to the peptide/DNA complex, up to periods of 120
min (Fig. 6B). The temperature- and time-dependent prop-
erties of this transduction suggested that peptide-mediated
gene transfer is at least partly by endocytic pathway. Next,
we examined the effect of chloroquine, an inhibitor of the
acidification of endocytic vesicles, on peptide-mediated
gene transfer. Our result showed that chloroquine addition
enhanced the transfection, suggesting that internalization of
the peptide/DNA complex is mediated by endocytosis
pathway (Fig. 5).3.5. Peptide-mediated delivery of HSV-TK gene into tumor
cells
The introduction of the HSV-TK gene specifically
sensitizes tumor cells to the anti-herpes drug GCV, result-
ing in cell death by premature chain termination within
replicating DNA. This gene has been employed in a
number of cancer gene therapy protocols [25,26]. To
determine the suitability of arginine peptide for gene
therapy, we tested the efficiency of HSV-TK gene delivery
into HeLa cells. Following transfection, cells were incu-
bated for an additional 4 days with 10 AM GCV. The
cytotoxicity of cells was determined using MTT assay. As
shown in Fig. 7, the control cells were insensitive to GCV
treatment, whereas the HSV-TK-containing cells were
susceptible to GCV-related cytotoxicity. Fig. 7 also dem-
onstrates a much greater cytotoxicity in peptide-mediated
sica Acta 1640 (2003) 129–136
Fig. 7. The cytotoxicity of GCV on the HSV-TK transfected HeLa cells.
HeLa cells were transfected with plasmid encoding HSV-TK by peptide-
mediated method, and then exposed to 10 AM GCV for 4 days. After 4-day
incubation, cell cytotoxicity was determined by MTT assay. Experiments
were performed at least three times at each sample; data shown are mean
value and S.D. for each measurement.
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transfected cells.4. Discussion
The efficient delivery of genes into cultured cells or in
vivo tissues is essential to establishing a rational, physio-
logical basis for gene therapies. Here we demonstrate that a
short basic peptide can efficiently mediate exogenous DNA
transfection into cells. These findings suggest potential
benefits to gene therapy and gene delivery for a range of
model organisms.
Basic peptides have been extensively employed to intro-
duce foreign protein into cells [3,4,27,28]. It has been
demonstrated that these peptides can translocate proteins
into cells without significant cytotoxicity either by fusion
with the target protein [29] or by chemical linking [2,10].
These peptides do not have any specific primary or secon-
dary structures in common other than the basic residues in
the sequences. A recent report shows that many of these
peptides contain either RNA or DNA binding motifs [9,12].
Moreover, presentation of Tat peptide molecule on the sur-
face of lambda phage, or of liposomes, successfully deliv-
ered the packaged genes into target cells [2,30]. The nature
of the basic peptide in efficient protein transduction and in
nucleic acid binding capability prompted us to explore the
possibility of DNA transfection by these peptides.
Efficient gene delivery system must meet several criteria.
(1) The overall efficiency of the carrier for the DNA must behigh level. (2) The DNA must be protected against, or
resistant to, degradation by enzymes such as DNase during
transfection process. (3) The carrier/DNA complex must be
able to cross the cell membrane and overcome the intra-
cellular barriers in nuclear localizing. (4) The transferred
gene must be capable of persistently high expression. (5)
The carriers should have minimal cytotoxicity. (6) And the
carrier and DNA complex must be stable in serum-contain-
ing cell culture medium [31,32].
As demonstrated in our gel retardation assay, arginine
peptide not only exhibits high affinity for nucleic acids but
also protects them against nuclease degradation, indicating
that binding arginine peptide with plasmid DNA forms very
stable complex. Peptide/DNA complex also successfully
transfected the cell lines as a series. In addition, our results
present that transfection efficiency of peptide/DNA complex
in 293T cells is much greater than the efficiencies of the
commercially available nonviral transfection agents Lip-
ofectin and GenePORTER2. It is known that polycationic
gene delivery system, one of the most prevalent nonviral
delivery systems, can lead to cytotoxicity as a direct result
of the polycations [33,34]. To reduce the severity of this
effect, cationic density-optimized side chains have been
introduced [15]. We observe that the arginine peptide is
non-cytotoxic and obviates serum sensitivity, which ad-
dresses the concern that the DNA-transporting properties
of nonviral vectors might be sensitive to serum-borne
nuclease and protease [35]. These considerations further
support that arginine peptide may become a useful tool of
gene delivery system.
The precise mechanism for intracellular delivery of
macromolecules by basic peptides is at present poorly
understood. Cell surface proteoglycan and low-density lip-
oprotein receptor protein have been earlier implicated in the
translocation of the Tat protein [20,24,10]. The involvement
of proteoglycan in cation-mediated gene transfer has also
been reported [22]. Proteoglycan consists of a heterogene-
ous group of proteins substituted with long linear polysul-
fated chains, to yield negatively charged glycosamino-
glycans such as chondroitin sulfate, heparan sulfate, and
dermatan sulfate [23,36]. The negatively charged sulfate
groups of glycosaminoglycans may be responsible for
interaction of polybasic compounds [10]. Our data showed
that treatment of cell with heparan sulfate, heparinase III,
chondroitin sulfate B, C, and chondroitinase ABC signifi-
cantly reduced marker gene expression, suggesting that
proteoglycan is involved in this process. The expression
of marker gene was also partially inhibited at 4 jC incuba-
tion, indicating that typical endocytosis mechanisms would
not be the only pathway in peptide/DNA internalization. In
contrast, transfection efficiency was increased by the addi-
tion of chloroquine. This reagent inhibits degradation of
peptide/DNA complex by lysosomal hydrolases and affects
the efficiency of endocytosis-mediated gene transfer in
stimulatory manner [37]. These results suggest the possi-
bility of more than one mechanism impinging on arginine
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dependence on the number of arginine residues for the
transfection efficiency. The R15 peptides showed the high-
est level of transfection efficiency in our observations.
However, recent study has reported that cellular uptake of
arginine only peptide was more efficient with R8 than R16
[18]. At this stage, it is not clear why a different optimal
number of arginine residues is required for free peptide
translocation and for peptide-mediated transfection. One
possible explanation is that complex formation of arginine
peptide with DNA causes to change its physiological and
chemical characterizations such as charge, size, and degree
of aggregation.
The essence of gene therapy is delivering an exogenous
gene into target cells and ensuring that it will be expressed
so as to inactivate particular cellular components or path-
ways—such as cancerous growth—under the control of
specific genes [38]. Suicide gene therapy based on GCV
metabolism and HSV-TK transgenes has been widely used
to selectively kill tumor cells in clinical cases [39]. To assess
the potential use of the delivery system reported here, we
transferred HSV-TK gene into tumor cells. We have dem-
onstrated that the HSV-TK gene was successfully expressed
and killed tumor cells following treatment of GCV.
In conclusion, our work demonstrates that arginine pep-
tide-mediated gene delivery systems are less toxic to target
cells, reduce the serum sensitivity, and require simpler
manipulation than other gene delivery methods, thus offer-
ing the potential of significantly improved gene delivery for
disease therapies. Further studies will focus on raising the
transfection efficiency, through systematic evaluation of
various technical factors. In this regard, optimizing such
factors as (i) incubation temperature, (ii) peptide/DNA
complex incubation period, (iii) cell/complex incubation
period, and (iv) steps to control cell and complex aggrega-
tion are hoped to improve the overall efficiencies of basic
peptide-mediated delivery. We are also considering the
effects of detergents, incubation, and the ratio of cells to
complexes in avoiding potential peptide aggregation.Acknowledgements
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